Pfizer Tests The Luck Of The Irish; Will The US Let Its Pharma Pot Of Gold Go?
Executive Summary
Pfizer and Allergan confirmed they are in friendly merger negotiations. Now the question is if Pfizer can afford to pay for Allergan and will the US government let a pharma giant the size of Pfizer go without a fight.
You may also be interested in...
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.